Background: While androgen deprivation therapy (ADT) is a common treatment for prostate cancer, little is known regarding its long-term health effects, particularly as it relates to the development of second primary malignancies. Therefore, the goal of this study was to assess the association between ADT use and second primary malignancies among men diagnosed with localized prostate cancer.
Introduction
While androgen deprivation therapy (ADT) is a common treatment for prostate cancer, little is known regarding its long-term health effects. However, the use of ADT remains a common, albeit controversial, treatment option for localized prostate cancer (1) . Previous studies have linked ADT use to increased risk of osteoporosis, fractures, and cardiovascular outcomes (2-4). Gillessen and colleagues found a positive association between longterm use of ADT and the development of colorectal cancer (5) . However, it remains unclear whether the use of ADT increases the risk of other second primary malignancies. Because ADT is associated with other known risk factors for cancer such as diabetes and obesity (2, 3, 6) , its use may potentially influence second cancer development through these pathways. Also, it has been hypothesized that androgens may protect against carcinogenesis (7, 8) . It is plausible that the suppression of androgen may then promote the progression of carcinogenesis. Therefore, the goal of this study was to assess the association between ADT use and second primary malignancies among a cohort of men diagnosed with localized prostate cancer.
Materials and Methods
A retrospective cohort of 24,038 men ages 18 years and older enrolled in Kaiser Permanente Southern California (Pasadena, CA) health plan who were diagnosed with localized prostate cancer between 1998 and 2007 were followed through 2009 for the development of second primary cancers as identified through the National Cancer Institute-Surveillance Epidemiology and End Results (NCI-SEER)-affiliated cancer registry. Men diagnosed with a second primary cancer or who died from it within 6 months of prostate cancer diagnosis (N ¼ 173), had a history of chemotherapy treatment (n ¼ 29), or who underwent orchiectomy (N ¼ 82) were excluded. ADT use was defined as any use of a gonadotropin-releasing hormone (GnRH) agonist and was treated as a timedependent exposure so that men could contribute person-time to the ADT group after treatment initiation and to the no ADT group either before ADT initiation, or if they never received ADT during follow-up. Proportional hazards regression was used to estimate the risk of a second primary cancer among men who were treated with ADT compared with men who were not after adjustment for age, race, date of prostate cancer diagnosis, utilization, prostate cancer clinical stage, Gleason score, and radiation therapy. Censoring occurred at development of second cancer, death, health plan disenrollment, or end of study, whichever occurred first. This study had 90% power to detect a difference in effect of 1.25 or more (0.8 or smaller). All analyses were conducted using SAS 9.3 with a a level of 0.05.
Results
Of the 24,038 men with localized prostate cancer, 1,359 (5.7%) were diagnosed with a second primary cancer during follow-up. The most common site was colorectal (0.78%), followed by lung/bronchus (0.75%), bladder (0.55%), and kidney (0.32%). Men who were diagnosed with a second primary cancer were older, had lower income and education, and were more likely to have a history of type 2 diabetes and hypertension. (Table 1 ) Men who were treated with ADT were equally as likely to develop any second primary cancer (regardless of site) as men who were not treated with ADT after adjustment for age, race, date of prostate cancer diagnosis, utilization, clinical stage, Gleason score, and radiotherapy (HR, 1.10; 95% confidence interval (CI), 0.98-1.22; Table 2 ). Radiotherapy, diabetes, and obesity did not modify the association between ADT use and second primary cancer risk. (Data not shown)
Discussion
In this study of men with localized prostate cancer, ADT therapy was not associated with an increased risk of second primary malignancies. In contrast to a previous study (5) , ADT use was also not associated with an increased risk of colorectal cancer. It is possible that the inclusion of younger men in this study may have resulted in a lower risk of secondary cancers overall, thus resulting in more conservative estimates of the risk of second primary cancers than reported previously.
While this study is one of the first to evaluate the risk of developing any type of second primary malignancy after ADT treatment, there are potential limitations to consider. Because of the complexities of determining injectable drug dosing in our data, ADT dose and duration were not available. Therefore, whether ADT dose influences second primary cancer development could not be assessed. Confounding by factors not measured in this study, such as the use of screening for secondary cancers, might have influenced the results. However, the use of screening is not thought to differ by ADT use, thus limiting the effect of this bias. Finally, because this study included only men with localized prostate cancer, generalizing these findings to men with advanced disease is limited.
Conclusions
In conclusion, ADT treatment for localized prostate cancer was not associated with an increased risk of second primary cancers. When evaluating the risks and benefits of using ADT as a treatment for localized prostate cancer, considering the risk of secondary cancers may not be clinically important.
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